ACACA and metabolic dysfunction-associated steatotic liver disease: In this study, AMY significantly altered the expressions of SREBP1 and PPAR-α, and inhibited the lipogenic factors CD36, FAS, and ACC in hepatic tissues, indicating that AMY ameliorated NAFLD through the suppression of lipogenesis and the promotion of fatty acid oxidation.